Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C3H6O3 |
| Molecular Weight | 90.0779 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@H](O)C(O)=O
InChI
InChIKey=JVTAAEKCZFNVCJ-REOHCLBHSA-N
InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/t2-/m0/s1
| Molecular Formula | C3H6O3 |
| Molecular Weight | 90.0779 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lactic Acid, L- (L-lactic acid, L-lactate) is the levorotatory isomer of lactic acid, the biologically active isoform in humans. Lactic acid or lactate is produced during fermentation from pyruvate by lactate dehydrogenase. Lactate dehydrogenase is isomer-specific so that production and metabolism of D-lactate require D-LDH and L-lactate requires L-LDH. Mammalian cells only contain L-LDH so that in humans the lactate produced is almost exclusively L-lactate. Carbohydrate-fermenting bacterial species (e.g. lactobacillus spp) have by contrast both enzymes and therefore the capacity to produce both D-lactate and L-lactate. L-lactic acid is the primary agonist of hydroxycarboxylic acid receptor 1 (HCA1), which is a Gi/o-coupled G protein-coupled receptor (GPCR). Poly-L-lactic acid is an absorbable, semi-permanent, injectable implant that can be used to restore volume and stimulate collagen formation gradually. It is FDA-approved for the correction of facial fat loss associated with antiretroviral therapy-induced lipoatrophy in HIV patients. It is FDA-approved for use in immunocompetent people for the correction of nasolabial fold deficiencies and other facial wrinkles. It has been used off-label to enhance the cheeks, hands, neck, thighs, gluteal enhancement and chest wall deformities, such as pectus excavatum or thoracic deformities secondary to surgical procedures.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Q9BXC0 Gene ID: 27198.0 Gene Symbol: HCAR1 Target Organism: Homo sapiens (Human) |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | PRISMASOL Approved UsePRISMASOL solution is indicated as a replacement solution in Continuous Renal Replacement Therapy (CRRT) and in case of drug poisoning when CRRT is used to remove dialyzable substances. Launch Date1.16164801E12 |
PubMed
| Title | Date | PubMed |
|---|---|---|
| High resolution 1H n.m.r. studies of vertebrate blood and plasma. | 1983 Jun 1 |
|
| Lactate- and isoproterenol-induced panic attacks in panic disorder patients and controls. | 1988 Feb |
|
| Cloning of a lactate dehydrogenase gene from Clostridium acetobutylicum B643 and expression in Escherichia coli. | 1990 Dec |
|
| 1H NMR characterization of normal human cerebrospinal fluid and the detection of methylmalonic acid in a vitamin B12 deficient patient. | 1991 Aug |
|
| Malignant ventricular tachycardia during propafenone treatment in a child with junctional automatic tachycardia: effectiveness of intravenous molar sodium lactate. | 1991 May |
|
| Lactate and pyruvate concentrations in capillary blood from newborns. | 1994 Sep |
|
| Intracellular flux analysis applied to the effect of dissolved oxygen on hybridomas. | 1995 Dec |
|
| Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. | 1998 |
|
| Paraquat-induced renal injury studied by 1H nuclear magnetic resonance spectroscopy of urine. | 1998 Jun |
|
| L-lactic acid as a mosquito (Diptera: Culicidae) repellent on human and mouse skin. | 2001 Jan |
|
| Optimisation of media and cultivation conditions for L(+)(S)-lactic acid production by Lactobacillus casei NRRL B-441. | 2001 Jul |
|
| A double-blind, randomized, placebo-controlled pilot study to investigate the effects of finasteride combined with a biodegradable self-reinforced poly L-lactic acid spiral stent in patients with urinary retention caused by bladder outlet obstruction from benign prostatic hyperplasia. | 2001 Jul |
|
| The 12,13-diol cyclization approach for a truly stereocontrolled total synthesis of epothilone B and the synthesis of a conformationally restrained analogue. | 2001 May 18 |
|
| Asymmetric intramolecular [2 + 2] photocycloadditions: alpha- and beta-hydroxy acids as chiral tether groups. | 2002 Feb 22 |
|
| Structure of the O-polysaccharide of Proteus penneri 28 and Proteus vulgaris O31 and classification of P. penneri 26 and 28 in Proteus serogroup O31. | 2003 Oct 24 |
|
| Automated no-carrier-added synthesis of [1-11C]-labeled D- and L-enantiomers of lactic acid. | 2006 Dec |
|
| Remote ischaemic preconditioning protects against cardiopulmonary bypass-induced tissue injury: a preclinical study. | 2006 Oct |
|
| Physiological and behavioral effects of naloxone and lactate in normal volunteers with relevance to the pathophysiology of panic disorder. | 2007 Jan 15 |
|
| Role of GPR81 in lactate-mediated reduction of adipose lipolysis. | 2008 Dec 19 |
|
| Facile alcoholysis of L-lactide catalysed by Group 1 and 2 metal complexes. | 2008 Jun 21 |
|
| Design of a "new motif" with beta-amino acids and alpha-aminoxy acids: synthesis of hybrid peptides with 12/10-helix. | 2008 May 16 |
|
| Perioperative chronic use of statins and the risk of muscle complaints in patients undergoing knee and hip endoprosthesis surgery. | 2010 Mar |
|
| Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. | 2013 Jun |
Sample Use Guides
Facial fat loss (lipoatrophy) Sculptra (Poly-L-lactic acid): Intradermal or SubQ: ~0.05-0.2 mL per individual injection depending on technique used; ~20 injections may be needed per cheek. Treatment should be individualized. Separate treatments by ≥2 weeks. Typical course involves 3-6 treatments. Supplemental injections may be needed. Do not overfill contour deficiency. For patients with severe facial fat loss, the average treatment requires ~1 vial per cheek area per treatment.
Route of Administration:
Other
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:58 UTC 2023
by
admin
on
Fri Dec 15 15:05:58 UTC 2023
|
| Record UNII |
F9S9FFU82N
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
EPA PESTICIDE CODE |
128929
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1356734
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
SUB11686MIG
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
F9S9FFU82N
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
SUB35198
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
2462499
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
C61808
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
F9S9FFU82N
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
DTXSID6034689
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
m6655
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | Merck Index | ||
|
422
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
DB14475
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
107689
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
100000076647
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
79-33-4
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY | |||
|
201-196-2
Created by
admin on Fri Dec 15 15:05:58 UTC 2023 , Edited by admin on Fri Dec 15 15:05:58 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT | |||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TRANSPORTER -> SUBSTRATE |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
